Those Viral Bodega Peptides Aren’t Actually Peptides
A Brooklyn bodega sold peptide vials that turned out to be mislabeled, sparking concerns about the safety and legality of over‑the‑counter peptide sales. Independent lab tests found no active ingredients in the samples, highlighting a broader issue with unregulated peptide vendors.
A small shop on Bedford Avenue in Brooklyn, New York, called Mr. Green, recently caught the eye of the internet when it sold tiny vials of injectable peptides. These peptides, marketed for everything from weight loss to injury recovery, had become a summer sensation on social media. The shop’s clerk packed four different samples—PT‑141, BPC‑157, NAD+, and retatrutide—into an unlabeled paper bag and handed them to a curious customer who was eager to test their authenticity.
To verify the contents, the customer sent the vials to Finnrick, an Austin‑based startup that offers independent peptide testing. Finnrick does not conduct the testing itself; instead, it partners with external laboratories to analyze samples for purity, contaminants, and the presence of the claimed active ingredients. After a few weeks, the results arrived: the vials contained low levels of heavy metals and endotoxins, suggesting they were not immediately toxic. However, the crucial finding was that none of the samples contained the peptides they were labeled with. For example, the BPC‑157 vial had no BPC‑157 at all.
What Went Wrong?
Peptides are delicate molecules that can degrade if stored improperly. They often require refrigeration and protection from light and temperature fluctuations. Mislabeling can occur for a variety of reasons: a vendor may have sold the wrong product, the sample may have been contaminated during manufacturing, or the product may have been intentionally falsified. In this case, the lack of any detectable active ingredient points to either a severe labeling error or deliberate fraud.
Marco Krause, CEO of the laboratory that performed the analysis for Finnrick, explained that the lab’s role is to compare the sample against a known standard. “We run it against a standard and verify whether or not it’s the right compound,” he said. The test results, therefore, do not reveal what the vials actually contain—only that they do not contain what they claim to.
The Broader Peptide Market
Peptide sales have exploded in recent years, fueled by endorsements from high‑profile figures such as former U.S. Health Secretary Robert F. Kennedy Jr. and popular podcaster Joe Rogan. While some peptides are legitimate pharmaceutical drugs—like GLP‑1s and insulin—many of the buzzworthy compounds have never undergone the rigorous drug approval process. Consequently, they are not legally sold for human consumption in the United States. The Mr. Green sign advertised the products as “research use only,” a phrase that labs sometimes use to shield themselves from liability, but it does not guarantee safety or authenticity.
Finnrick’s CEO, Raphaël Mazoyer, noted an uptick in samples that turned out to be “just duds.” He attributes this trend to the rise of turnkey services that enable anyone to start a peptide business. “There are a whole bunch of labels popping up that have the same upstream vendor,” he said. The industry’s fragmented nature means that a single unreliable supplier can affect many brands.
Other Cases of Mislabeling
Similar problems have surfaced elsewhere. Jeff Colhoun, founder of the research‑peptide directory Peptide Critic, purchased retatrutide and NAD+ vials from a nearby smoke shop and had them tested by Analytical Formulations in Texas. The lab could not positively identify the substances, indicating contamination or severe degradation. Colhoun has heard from other vendors that have received comparable results, underscoring the risk of buying peptides without proper batch testing.
INDR Labs, a vendor that sold the same products, has become less accessible online after the lab’s certificate of analysis was removed from public view. The company claims its certificates come from Vanguard Laboratory, but Vanguard has denied issuing any such documents. This chain of events highlights the opaque nature of the peptide supply chain.
Regulatory and Safety Concerns
Regulators warn that selling peptides labeled “research use only” to consumers is illegal. The FDA has taken enforcement actions against individuals and companies that import and sell unapproved peptides, including a recent case in South Bend, Indiana, where a man received a six‑year sentence for selling adulterated peptides imported from China. Despite these actions, enforcement remains sporadic, and the market continues to grow, with estimates suggesting it could be worth up to $3 billion.
Experts caution that consumers who purchase these products risk serious harm. A woman died in the Bronx after receiving an injection from an unlicensed medical spa, a tragedy that may have been linked to contaminated or mislabeled peptides. Legal scholars like Darshan Kulkarni point out that the lack of quality controls in the peptide market means that safety, efficacy, and accurate labeling cannot be guaranteed.
While a mislabeled vial may simply be a financial loss, the presence of harmful contaminants could have dire health consequences. The FDA continues to monitor the market and has warned telehealth companies and other vendors about false or misleading claims regarding peptide products.
What’s Next?
Mr. Green has not responded to inquiries, and the peptide menu in the shop’s window has disappeared, though the products remain available inside. The broader issue remains: consumers can still access unregulated peptides through brick‑and‑mortar stores, online vendors, and telehealth platforms. Until stricter enforcement and clearer labeling standards are in place, the risk of purchasing fake or dangerous peptides will persist.
For now, the takeaway is clear: if you’re considering a peptide, verify its authenticity through a reputable laboratory and be wary of products sold as “research use only” in everyday retail settings.
Why it matters
The discovery that over‑the‑counter peptide vials can be mislabeled or contain no active ingredients exposes a dangerous gap in consumer safety and regulatory oversight, putting people at risk of ineffective or harmful substances.
Key points
- Bodega sold mislabeled peptide vials that lacked active ingredients
- Independent lab testing confirmed absence of claimed peptides
- The peptide market is largely unregulated and often sold as “research use only”
- Similar mislabeling incidents have occurred with other vendors
- Regulatory bodies have taken limited enforcement actions, leaving gaps
- Consumers risk health hazards from contaminated or fake peptides
Frequently asked questions
What are peptides used for?
Peptides are short chains of amino acids that can be used for medical purposes such as weight loss, muscle recovery, and hormone regulation, but many are not approved by the FDA for human use.
How can I verify if a peptide is genuine?
Send the sample to an independent testing laboratory that can analyze for purity, contaminants, and the presence of the claimed active ingredient.
Are peptides sold in stores legal?
Most peptides sold for “research use only” are not approved for human consumption in the U.S., making their sale to consumers illegal.
